XBiotech Reports $1.8 Million Net Loss for Q2 2025, Down from $13 Million Last Year

XBiotech Inc. reported a net loss of $1.8 million for the three months ended June 30, 2025, a significant decrease from the $13.0 million loss recorded in the same period of the previous year. For the six months ended June 30, 2025, the company posted a net loss of $12.6 million, down from $23.0 million in the prior year. The reduction in losses is attributed to a decrease in operating expenses, which totaled $6.3 million for the second quarter of 2025, compared to $15.0 million in the same quarter of 2024. The company’s cash and cash equivalents stood at $152.9 million at the end of the reporting period, down from $188.5 million a year earlier.

The decline in operating expenses was primarily driven by a reduction in research and development costs, which fell to $5.3 million for the three months ended June 30, 2025, compared to $13.0 million in the same period of 2024. This decrease was largely due to the absence of active clinical trials during the quarter and a shift in the timing of a significant bonus to the CEO, which was granted earlier in the year. General and administrative expenses also decreased to $1.0 million from $2.0 million year-over-year, reflecting lower salaries and related expenses.

XBiotech's operational metrics indicate a stable workforce, with 92 employees as of June 30, 2025. The company continues to focus on its True Human™ monoclonal antibody pipeline, which is in various stages of development. Despite the current financial losses, XBiotech is optimistic about its future, stating that its cash reserves are expected to support its operations for at least the next 12 months. The company does not anticipate generating revenue in 2025, as it continues to advance its drug candidates through preclinical and clinical testing.

In terms of strategic developments, XBiotech has been actively managing its financial structure, including a $10 million convertible loan from its CEO, which was fully repaid in January 2025. The company has also maintained a focus on its research and development efforts, with total expenses in this area amounting to $366.6 million since its inception. The company is currently evaluating its clinical data and pipeline to determine the next steps for its drug candidates.

Looking ahead, XBiotech acknowledges the need for significant revenue generation to achieve profitability, which may not be realized until its drug candidates receive regulatory approval and are successfully commercialized. The company remains committed to its research initiatives and is preparing for potential future clinical trials as it continues to develop its therapeutic products.